Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 10, 2021
- Accepted in final form December 3, 2021
- First Published January 28, 2022.
Author Disclosures
- Mickael Denis, MD (mickael-denis{at}hotmail.fr),
- Jean-Philippe Woillez, MD, PhD (docteur.jp.woillez{at}wanadoo.fr),
- Vasily M. Smirnov, MD (vasily.smirnov{at}chu-lille.fr),
- Elodie Drumez (edrumezchr{at}gmail.com),
- Julien Lannoy, MD (julien.lannoy{at}chru-lille.fr),
- Julie Boucher, MD (julie.boucher{at}chru-lille.fr),
- Mickael Zedet, MD (mickael.zedet{at}hotmail.fr),
- Jean-Pierre Pruvo, MD, PhD (jppruvo{at}gmail.com),
- Julien Labreuche (julien.labreuche.chru{at}gmail.com),
- Helene Zephir, MD, PhD (helene.zephir{at}chru-lille.fr),
- Xavier Leclerc, MD, PhD (xavier.leclerc{at}chru-lille.fr) and
- Olivier Outteryck, MD, PhD
- Mickael Denis, MD (mickael-denis{at}hotmail.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Philippe Woillez, MD, PhD (docteur.jp.woillez{at}wanadoo.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vasily M. Smirnov, MD (vasily.smirnov{at}chu-lille.fr),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Elodie Drumez (edrumezchr{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julien Lannoy, MD (julien.lannoy{at}chru-lille.fr),
NONE
(1)Roche funding for travel AAN 2019 at Philadelphia (2)Sanofi Genzyme funding for travel ECTRIMS 2017 at Amsterdam
NONE
(1)Lettre du Neurologue e-journal ECTRIMS 2018, writer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julie Boucher, MD (julie.boucher{at}chru-lille.fr),
(1) Commercial : Biogen (2) Commercial : MERCK (3) Commercial : SANOFI (4) Commercial : NOVARTIS
NONE
(1) Commercial : MERCK (case report) (2) COMMERCIAL : SANOFI GENZYME (Journée du Touquet)
NONE
NONE
NONE
NONE
NONE
NONE
(1) Commercial Congress (inscription) : ECTRIMS (NOVARTIS) (2) Commercial Congress (inscription) : JNLF MERCK (4) Commercial Congress (rapporteur ECTRIMS 2020 BIOGEN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mickael Zedet, MD (mickael.zedet{at}hotmail.fr),
I receive consultations fees from Alexion.
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Pierre Pruvo, MD, PhD (jppruvo{at}gmail.com),
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Julien Labreuche (julien.labreuche.chru{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Helene Zephir, MD, PhD (helene.zephir{at}chru-lille.fr),
I received consulting fees from ROCHE, BIOGENIDEC, NOVARTIS, SANOFI, ALEXION, BMS.
NONE
NONE
NONE
NONE
NONE
NONE
I received consultancies fees from BIOGENIDEC, MERCK, BAYER, NOVARTIS, SANOFI,BMS, ALEXION
NONE
NONE
NONE
I received research support grants from ROCHE
NONE
I received research support grants from Ligue Française contre la sclérose en plaques and from ARSEP (Association de recherche contre la Sclérose en plaques)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Leclerc, MD, PhD (xavier.leclerc{at}chru-lille.fr) and
NONE
NONE
NONE
Editor in chief of the Journal of Neuroradiology between 2007 and 2011.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Outteryck, MD, PhD
NONE
NONE
(1)Biogen Idec; Funding for travel and speaker honoraria (2)Bayer-Pharma; Funding for travel and speaker honoraria (3)Sanofi; Funding for travel (4)Merk-Serono; Funding for travel (5)TEVA; Funding for travel (6)Roche; Funding for travel and speaker honoraria (6)Novartis; Funding for travel
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Univ. Lille (M.D., J.-P.P., X.L., O.O.), Department of Neuroradiology, INSERM, CHU Lille, U1172—Lille Neurosciences Institute; Univ. Lille (J.-P.W., V.M.S.), Department of Visual Explorations and Neuro-Ophthalmology, Hôpital Roger Salengro, CHU Lille; Univ. Lille (E.D., Julien Labreuche), CHU Lille, EA 2694—Santé publique: épidémiologie et qualité des soins, Department of Biostatistics; and Univ. Lille (Julien Lannoy, J.B., M.Z., H.Z.), Department of Neurology, INSERM, CHU Lille, U1172–Lille Neurosciences Institute, France.
- Correspondence
Dr. Outteryck olivier.outteryck{at}chru-lille.fr
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.